# Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Source: https://onco.cc/trials/nct03458260/  
OnCo record `nct03458260` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pixantrone, Ifosfamide, Etoposide and Rituximab in Non-Hodgkin lymphoma, run by The Lymphoma Academic Research Organisation, completed.

## Summary

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma is a phase 2 interventional study registered as NCT03458260 by The Lymphoma Academic Research Organisation, with 74 participants recorded, started 2018-12-26 and reaching its primary completion in 2024-12-24. Interventions recorded: Pixantrone, Ifosfamide, Etoposide, Rituximab, Transplant. Conditions recorded: Aggressive Non-Hodgkin Lymphoma.

Linked to the drug Pixantrone because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03458260
- Phase: 2
- Setting: A Multicentre, Phase II, Open Label, Single Arm Study of Pixantrone in Patients With CD20-positive Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated With Rituximab, Ifosfamide and Etoposide.
- Sponsor: The Lymphoma Academic Research Organisation
- Enrolled: 74

## Sources

- ClinicalTrials.gov NCT03458260: https://clinicaltrials.gov/study/NCT03458260

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Etoposide](https://onco.cc/drugs/etoposide/), [Ifosfamide](https://onco.cc/drugs/ifosfamide/), [Pixantrone](https://onco.cc/drugs/pixantrone/), [Rituximab](https://onco.cc/drugs/rituximab/)

---
JSON: https://onco.cc/api/v1/entities/nct03458260.json